To determine whether targeting EEF2K would affect melanoma tumour development similar to what we have observed in breast cancer [14] when EEF2K was knocked down, an established rapid approach was used [29,30,31], which involved nucleofecting UACC 903 melanoma cells with 200 pmole of EEF2K, BRAF or scrambled siRNAs and 24 h later, injecting these cells subcutaneously into the flanks of nude mice. The gene discussed is EEF2K; the disease is melanoma.